Callio Therapeutics appoints Chris Hassig as chief scientific officer, coming from Boundless Bio
read at STAT ↗Positive
STAT+ regularly highlights personnel changes across the pharmaceutical sector. In its latest column the outlet reports a new senior appointment at Callio Therapeutics.
The company has hired Chris Hassig to serve as chief scientific officer. Hassig previously held the same title at Boundless Bio, bringing experience in drug development and research leadership.
The announcement reflects ongoing talent mobility in the industry, and the column invites readers to submit similar hiring, promotion or departure news for future coverage.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Up and down the ladder: The latest comings and goings”
read at STAT ↗459 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that